| Primary |
| Ovarian Cancer |
18.0% |
| Drug Use For Unknown Indication |
10.6% |
| Product Used For Unknown Indication |
10.2% |
| Breast Cancer |
9.2% |
| Breast Cancer Metastatic |
8.2% |
| Multiple Myeloma |
7.3% |
| Prophylaxis |
5.2% |
| Premedication |
5.0% |
| Burkitt's Lymphoma |
4.6% |
| Non-hodgkin's Lymphoma |
3.4% |
| Chronic Lymphocytic Leukaemia |
2.7% |
| Ovarian Cancer Recurrent |
2.1% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Ovarian Cancer Metastatic |
1.9% |
| Drug Exposure During Pregnancy |
1.8% |
| Anaplastic Large Cell Lymphoma T- And Null-cell Types |
1.6% |
| Lymphoma |
1.6% |
| Kaposi's Sarcoma |
1.5% |
| Peripheral T-cell Lymphoma Unspecified |
1.5% |
| Routine Health Maintenance |
1.5% |
|
| Infusion Related Reaction |
11.1% |
| Vomiting |
8.7% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
8.2% |
| Death |
6.8% |
| Rash |
6.3% |
| Interstitial Lung Disease |
4.8% |
| Respiratory Failure |
4.8% |
| Thrombocytopenia |
4.8% |
| Paraesthesia |
4.3% |
| Skin Toxicity |
4.3% |
| Toxic Skin Eruption |
4.3% |
| Myocardial Infarction |
3.9% |
| Off Label Use |
3.9% |
| Dyspnoea |
3.4% |
| Neuropathy Peripheral |
3.4% |
| Pancytopenia |
3.4% |
| Renal Impairment |
3.4% |
| Skin Reaction |
3.4% |
| Tachycardia |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
|
| Secondary |
| Ovarian Cancer |
20.3% |
| Burkitt's Lymphoma |
11.8% |
| Drug Use For Unknown Indication |
10.4% |
| Product Used For Unknown Indication |
8.1% |
| Breast Cancer Metastatic |
7.6% |
| Premedication |
6.6% |
| Prophylaxis |
6.4% |
| Multiple Myeloma |
4.9% |
| Breast Cancer |
3.8% |
| Diffuse Large B-cell Lymphoma |
3.4% |
| Nausea |
2.1% |
| Ill-defined Disorder |
2.0% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.8% |
| Plasma Cell Myeloma |
1.8% |
| Immunosuppression |
1.7% |
| Chemotherapy |
1.7% |
| Kaposi's Sarcoma |
1.7% |
| Ovarian Cancer Recurrent |
1.6% |
| Hepatoblastoma |
1.4% |
| Cardiac Failure |
1.2% |
|
| Palmar-plantar Erythrodysaesthesia Syndrome |
11.2% |
| Infusion Related Reaction |
8.2% |
| Pancytopenia |
8.2% |
| Thrombocytopenia |
7.7% |
| Colitis Ischaemic |
6.1% |
| Vomiting |
6.1% |
| Bronchiolitis |
5.1% |
| Paraesthesia |
5.1% |
| Renal Impairment |
5.1% |
| Hypersensitivity |
4.1% |
| Skin Toxicity |
4.1% |
| Subileus |
4.1% |
| Septic Shock |
3.6% |
| Blood Hiv Rna Increased |
3.1% |
| Cerebral Haemorrhage |
3.1% |
| Off Label Use |
3.1% |
| Pyrexia |
3.1% |
| Skin Hyperpigmentation |
3.1% |
| Skin Reaction |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
16.4% |
| Hiv Infection |
13.2% |
| Breast Cancer Metastatic |
11.4% |
| Metastases To Bone |
7.1% |
| Breast Cancer |
6.4% |
| Ovarian Cancer |
5.3% |
| Hypertension |
4.3% |
| Lung Adenocarcinoma Stage Iv |
4.3% |
| Multiple Myeloma |
3.9% |
| Hodgkin's Disease |
3.2% |
| Lymphoma |
3.2% |
| Pain |
3.2% |
| Mantle Cell Lymphoma |
2.8% |
| Chemotherapy |
2.5% |
| Kaposi's Sarcoma |
2.5% |
| Nausea |
2.5% |
| Burkitt's Lymphoma |
2.1% |
| Diffuse Large B-cell Lymphoma |
2.1% |
| Neoplasm Malignant |
1.8% |
| Non-hodgkin's Lymphoma Stage Iv |
1.8% |
|
| Osteonecrosis |
14.3% |
| Malignant Neoplasm Progression |
10.7% |
| Thrombocytopenia |
10.7% |
| Disease Progression |
8.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
5.4% |
| Pneumonia |
5.4% |
| Squamous Cell Carcinoma |
5.4% |
| Visual Impairment |
5.4% |
| Encephalopathy |
3.6% |
| Kaposi's Sarcoma |
3.6% |
| Myelodysplastic Syndrome |
3.6% |
| Polyneuropathy |
3.6% |
| Pulmonary Toxicity |
3.6% |
| Wound Debridement |
3.6% |
| X-ray Dental |
3.6% |
| Abdominal Pain |
1.8% |
| Acute Myocardial Infarction |
1.8% |
| Angiosarcoma |
1.8% |
| Arterial Occlusive Disease |
1.8% |
| Breast Cancer |
1.8% |
|
| Interacting |
| Ovarian Cancer |
30.0% |
| Product Used For Unknown Indication |
30.0% |
| Breast Cancer Metastatic |
13.3% |
| Lymphoma |
8.3% |
| Prophylaxis |
5.0% |
| Nausea |
3.3% |
| Prophylaxis Of Nausea And Vomiting |
3.3% |
| Antiemetic Supportive Care |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Epilepsy |
1.7% |
| Premedication |
1.7% |
|
| Febrile Neutropenia |
28.6% |
| Thrombocytopenia |
21.4% |
| Vomiting |
21.4% |
| Transaminases Increased |
14.3% |
| Nausea |
7.1% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
7.1% |
|
